GSK/Sanofi vaccine delayed until end of 2021

A vaccine related to the novel coronavirus, which was being developed by GlaxoSmithKline and Sanofi, its French counterpart, will be delayed until the end of 2021, after initial results showed it had failed to produce a strong immune response in older people. The two companies were hoping to have regulatory approval for the candidate vaccine in the first half of 2021.